Pfizer’s Xeljanz follow-up abrocitinib gathers momentumPfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased Share XPfizer’s Xeljanz follow-up abrocitinib gathers momentumhttps://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/
Sanofi opens digital biologics manufacturing siteSanofi has opened a manufacturing facility in the US, one of the world’s first facilities using digital continuous Share XSanofi opens digital biologics manufacturing sitehttps://pharmaphorum.com/news/sanofi-opens-digital-biologics-manufacturing-site/
The digital future: Sanofi’s Marc SchwartzIn this series we speak to pharma leaders to get their views on the biggest trends in digital Share XThe digital future: Sanofi’s Marc Schwartzhttps://pharmaphorum.com/digital/the-digital-future-sanofis-marc-schwartz/
Sanofi’s Dupixent backed for nasal polyps use in EuropeSanofi and Regeneron’s fast-growing immunology drug Dupixent is on course for a third indication in Europe after being Share XSanofi’s Dupixent backed for nasal polyps use in Europehttps://pharmaphorum.com/news/sanofis-dupixent-backed-for-nasal-polyps-use-in-europe/
Novo and Sanofi make case for hypo-reducing insulins at EASDNovo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals Share XNovo and Sanofi make case for hypo-reducing insulins at EASDhttps://pharmaphorum.com/news/novo-and-sanofi-duke-it-out-at-easd-making-case-for-hypo-reducing-insulins/
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trialJohnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio Share XJanssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trialhttps://pharmaphorum.com/news/janssens-ms-pill-outshines-sanofis-aubagio-in-phase-3-trial/
Who will be the biggest pharma players in orphan drugs?New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Share XWho will be the biggest pharma players in orphan drugs?https://pharmaphorum.com/views-analysis-sales-marketing/who-will-be-the-biggest-pharma-players-in-orphan-drugs/
Mylan’s Lantus biosimilar held up by manufacturing issueMylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient Share XMylan’s Lantus biosimilar held up by manufacturing issuehttps://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
